<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Golimumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Golimumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Golimumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9086" href="/d/html/9086.html" rel="external">see "Golimumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="12212" href="/d/html/12212.html" rel="external">see "Golimumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7764598"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infection:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with golimumab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">Discontinue golimumab if a patient develops a serious infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Reported infections with tumor necrosis factor (TNF) blockers include the following:</p>
<p style="text-indent:-2em;margin-left:6em;">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before golimumab use and during therapy. Initiate treatment for latent infection prior to golimumab use.</p>
<p style="text-indent:-2em;margin-left:6em;">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk of invasive fungal infections who develop severe systemic illness.</p>
<p style="text-indent:-2em;margin-left:6em;">Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the risks and benefits of treatment prior to initiating therapy in patients with chronic or recurrent infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients closely for the development of signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7710508"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Simponi;</li>
<li>Simponi Aria</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869041"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Simponi;</li>
<li>Simponi I.V.</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28120041"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antipsoriatic Agent</span>;</li>
<li>
<span class="list-set-name">Antirheumatic, Disease Modifying</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F54940717"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7adb1123-e6d3-4193-a4da-4e4eab6e5b54">Juvenile idiopathic arthritis, polyarticular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA), polyarticular:</b> Children ≥2 years and Adolescents: Simponi Aria: IV: 80 mg/m<sup>2</sup>/dose at weeks 0, 4, and then every 8 weeks thereafter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b> Children ≥2 years and Adolescents: Simponi Aria: IV: 80 mg/m<sup>2</sup>/dose at weeks 0, 4, and then every 8 weeks thereafter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29140944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29140944'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction:</i></p>
<p style="text-indent:-2em;margin-left:8em;">&lt;45 kg: SUBQ: 90 mg/m<sup>2</sup> (maximum dose: 200 mg/dose) at week 0 followed by 45 mg/m<sup>2</sup> (maximum dose: 100 mg/dose) at week 2.</p>
<p style="text-indent:-2em;margin-left:8em;">≥45 kg: SUBQ: 200 mg/dose at week 0 followed by 100 mg at week 2.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i> (beginning at week 6):</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;45 kg: SUBQ: 45 mg/m<sup>2</sup>/dose every 4 weeks; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥45 kg: SUBQ: 100 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing based on an open-label pharmacokinetic trial of patients with moderately to severely active ulcerative colitis (n=35; median age: 15 years) receiving golimumab. Concomitant medications (eg, corticosteroids, thiopurines, methotrexate, 5-ASA) were continued in 85.7% of patients. At week 6, 21 patients (60%) had achieved Mayo clinical response, 15 (43%) had achieved clinical remission, and 19 (54%) had evidence of mucosal healing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29140944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29140944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: IV, SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">Demyelinating disorders: Consider discontinuing golimumab.</p>
<p style="text-indent:-2em;margin-left:6em;">Heart failure (new or worsening symptoms): Discontinue golimumab.</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity (anaphylactic or other serious allergic reaction): Discontinue golimumab.</p>
<p style="text-indent:-2em;margin-left:6em;">Infection (serious or opportunistic) or sepsis: Discontinue golimumab.</p>
<p style="text-indent:-2em;margin-left:6em;">Lupus-like syndrome (symptoms suggestive of lupus-like syndrome): Discontinue golimumab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54940759"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F54940760"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F7764854"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9086" href="/d/html/9086.html" rel="external">see "Golimumab: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Corticosteroids, <i>nonbiologic</i> disease-modifying antirheumatic drugs (DMARDs), and/or nonsteroidal anti-inflammatory drugs may be continued for the treatment of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Golimumab should <b>not</b> be used in combination with <i>biologic</i> DMARDs or Janus kinase (Jak) inhibitors.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ:</b> 50 mg once a month (either alone or in combination with methotrexate or other nonbiologic DMARDs).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ:</b> 50 mg once a month (either alone or in combination with methotrexate or other nonbiologic DMARDs).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis: Note:</b> For use as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy; may also be used off-label as an alternative to methotrexate in DMARD-naive patients with moderate to high disease activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter (in combination with methotrexate).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ:</b> 50 mg once a month (in combination with methotrexate).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis: SubQ:</b> Induction: 200 mg at week 0, then 100 mg at week 2, followed by maintenance therapy of 100 mg every 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="817fad1b-2b47-4cdb-aa3f-b5198ee7cd94">Axial spondyloarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Axial spondyloarthritis (active, nonradiographic) (off-label use): SubQ:</b> 50 mg once every 4 weeks for 16 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26139307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26139307'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990972"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988341"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F7764750"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer (IV: 17%, anti-dsDNA: &lt;1%; SUBQ: 4%, anti-dsDNA: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (SUBQ: Drug-tolerant EIA: 16% to 38%; IV: Drug-tolerant EIA: 19% to 31%; ~<sup>1</sup>/<sub>3</sub> to <sup>1</sup>/<sub>2</sub> were neutralizing)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (27% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (13% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (≤5%), leukopenia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤8%), increased serum aspartate aminotransferase (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (IV: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (1%), fungal infection (≤2%; may be invasive or superficial), viral infection (4% to 5%; includes herpes and influenza)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (SUBQ: 3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤2%), paresthesia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (2% to 3%), nasopharyngitis (≤6%), sinusitis (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Psoriasis (including new onset, palmoplantar, pustular psoriasis, or exacerbation of psoriasis)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Leukemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess, atypical mycobacterial infection, septic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Septic arthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Pyelonephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Opportunistic infection, sepsis, serious infection</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Reactivated tuberculosis, tuberculosis disease</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous skin disease, exfoliation of skin, lichenoid eruption, malignant melanoma, Merkel cell carcinoma, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, malignant lymphoma (including Hodgkin lymphoma and non-Hodgkins lymphoma), malignant neoplasm, neutropenia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis B, hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Demyelinating disease of the central nervous system, Guillain-Barré syndrome, multiple sclerosis, peripheral demyelinating polyneuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Infective bursitis, lupus-like syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, interstitial lung disease</p></div>
<div class="block coi drugH1Div" id="F7764747"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to golimumab, latex, or any other component of formulation or packaging; patients with severe infections (eg, sepsis, tuberculosis, opportunistic infections); moderate or severe heart failure (NYHA class III/IV)</p></div>
<div class="block war drugH1Div" id="F7764748"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Demyelinating disease: Rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, optic neuritis, Guillain-Barré syndrome, polyneuropathy) have been reported. Consider discontinuing in patients who develop peripheral or CNS demyelinating disorders during treatment. Use with caution in patients with pre-existing or recent onset central or peripheral nervous system demyelinating disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Worsening and new-onset heart failure (HF) (some fatal) have been reported with golimumab and other TNF-blockers. Monitor closely and discontinue with onset or worsening of symptoms. Use with caution in patients with HF or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Cases of pancytopenia and other significant cytopenias, including aplastic anemia, have been reported with TNF-blocking agents. Pancytopenia, leukopenia, neutropenia, and thrombocytopenia have occurred with golimumab. Consider discontinuing with significant hematologic abnormalities. Use with caution in patients with underlying hematologic disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B: Rare reactivation of hepatitis B virus (HBV), sometimes fatal, has occurred in chronic virus carriers, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients. Patients who test positive for HBV surface antigen should be referred for hepatitis B evaluation/treatment prior to golimumab initiation. Monitor for clinical and laboratory signs of active infection during and for several months following discontinuation of golimumab treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe systemic hypersensitivity reactions (including anaphylaxis) have been reported (some have occurred with the first dose) following intravenous and subcutaneous administration. Symptoms associated with reactions may include dyspnea, hives, nausea, and pruritus; reactions occurred during and within 1 hour of the start of IV infusion. Discontinue immediately if signs develop and initiate appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: <b>[US Boxed Warning]: Patients receiving golimumab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids). Tuberculosis (TB) disease (active TB) (or reactivation of tuberculosis infection [latent TB]), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including golimumab. May present as disseminated (rather than local) disease. Histoplasmosis testing (antigen or antibody) may be negative in some patients with active infection. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.</b> Caution should be exercised (consider risks versus benefits) when considering use in the elderly, patients taking concomitant immunosuppressants, patients with chronic or recurrent infection, patients who have been exposed to TB, patients with a history of opportunistic infection, patients with comorbid conditions that predispose them to infections (eg, diabetes), or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis). Do not initiate golimumab therapy in patients with active infection, including localized infection, which is clinically important. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescent patients receiving TNF-blocking agents.</b> Half of the malignancies reported in children were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included malignancies not typically observed in this population. The onset of malignancy was after a median of 30 months (range: 1 to 84 months) after the initiation of the TNF-blocking agent; most patients were receiving concomitant immunosuppressants. The impact of golimumab on the development and course of malignancy is not fully defined. Compared with the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving TNF-blocking agents. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis treated with a TNF-blocking agent and concurrent or prior azathioprine or mercaptopurine. Melanoma and Merkel cell carcinoma have been reported in patients receiving TNF-blocking agents including golimumab. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk for skin cancer. Consider risks versus benefits in patients with a known malignancy (other than a successfully treated nonmelanoma skin cancer) and if considering continuing treatment in a patient who develops a malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: <b>[US Boxed Warning]: Tuberculosis (disseminated or extrapulmonary) has been reported in patients receiving golimumab; both reactivation of TB infection (latent TB) and new infections have been reported. Patients should be evaluated for TB risk factors and TB infection (with a tuberculin skin test) prior to and during therapy. Treatment of TB infection should be initiated before use. Monitor for development of TB throughout treatment in patients with initial negative tuberculin skin tests,</b> patients currently receiving treatment for TB infection, or patients previously treated for TB; TB disease (active TB) has developed in this population during treatment with TNF-blocking agents. Use with caution in patients who have resided in regions where TB is endemic. Consider antituberculosis therapy if an adequate course of treatment cannot be confirmed in patients with a history of TB infection or disease or for patients with risk factors despite negative skin test. Prior to use, consider risks versus benefits in patients who have been exposed to TB.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; general incidence of infection is higher in elderly patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescent patients receiving TNF-blocking agents. </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage form specific issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some dosage forms may contain dry natural rubber (latex).</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration formulation/route: The safety and efficacy of switching between the IV and SubQ formulations and routes have not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of infection by live vaccines in patients receiving therapy. In clinical trials, humoral response to pneumococcal vaccine was not suppressed in psoriatic arthritis patients receiving golimumab. It is recommended to wait 6 months following the mother’s last infusion during pregnancy before administering any live vaccine to infants exposed to golimumab in utero.</p></div>
<div class="block foc drugH1Div" id="F7764860"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simponi Aria: 50 mg/4 mL (4 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simponi: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simponi: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F7764600"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321953"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Simponi Aria Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/4 mL (per mL): $599.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Simponi Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/0.5 mL (per 0.5 mL): $7,040.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $8,097.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Simponi Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/0.5 mL (per 0.5 mL): $7,040.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $8,097.08</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869042"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simponi I.V.: 50 mg/4 mL (4 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simponi: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simponi: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F54940783"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: <b>Note:</b> The safety and efficacy of switching between the IV and SUBQ formulations and routes have not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Dilution required prior to administration. Infuse over 30 minutes, using an infusion set with an in-line low protein-binding filter (≤0.22 micron). Do not infuse in the same line with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Administer SUBQ into thigh or lower abdomen (avoid areas within 2 inches of navel); may use the back of the upper arm if syringe only and dose not self-administered. Rotate injection sites and avoid injecting into tender, red, scaly, hard, or bruised skin, or areas with scars or stretch marks. If multiple injections are required for a single dose, administer each injection at a different site on the body.</p>
<p style="text-indent:-2em;margin-left:4em;">Autoinjector: Hold autoinjector firmly against clean skin and press button. A loud click is heard when injection has begun. Continue to hold autoinjector against skin until second click is heard (may take 3 to 15 seconds). Following second click, lift autoinjector from injection site.</p></div>
<div class="block adm drugH1Div" id="F7764856"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The safety and efficacy of switching between the IV and SUBQ formulations and routes have not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Dilute prior to use. Infuse over 30 minutes, using an infusion set with an in-line low protein-binding 0.22-micron filter. Do not infuse in the same line with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Allow syringe or autoinjector to sit at room temperature (~30 minutes) prior to administration; do not warm any other way. Rotate injection sites and avoid injecting into tender, red, scaly, hard, or bruised skin, or areas with scars or stretch marks. If multiple injections are required for a single dose, administer at different sites on body.</p>
<p style="text-indent:-2em;margin-left:4em;">Autoinjector: Hold autoinjector firmly against skin and inject SUBQ into thigh or lower abdomen (avoid the 2-inch area around the navel). A loud click is heard when injection has begun. Continue to hold autoinjector against skin until second click is heard (may take 3 to 15 seconds). Following second click, lift autoinjector from injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Syringe: Inject SUBQ into front of thigh, lower abdomen (avoid the 2-inch area around the navel), or back of upper arm (when given by caregiver or health care provider).</p></div>
<div class="block sts drugH1Div" id="F7764844"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials and syringes refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze. May also store at room temperature (≤25°C [77°F]) for ≤30 days; do not return to refrigerator. Do not shake. Store product in original carton to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Solutions diluted for infusion may be stored at room temperature for ≤4 hours.</p></div>
<div class="block meg drugH1Div" id="F7874784"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Simponi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F125289s146lbl.pdf%23page%3D38&amp;token=uFm09FCvEBOxiH6pUBzfCcvpUnO0B9HWgn2RhHSR0mus4mHlLQ9Y3mh2CDePgI5vKqCqOcP5nfg2lPPThsBoFvj%2BkOsyZrcZr1DrnkFtVC1wkMViiAItv4qxTT382NA%2B&amp;TOPIC_ID=129934" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125289s146lbl.pdf#page=38</a></p>
<p style="text-indent:-2em;margin-left:4em;">Simponi Aria: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F125433s032lbl.pdf%23page%3D34&amp;token=eWjSyOhiCoT8phEUGO3VhiTNeZCUFs0yp7dBZv0ZqgZQmvNnPrpvWdbYRpwHEmq0V8s6viHL4PfDccLEiF9426BWqklmSGVKmQ7%2FV2eud0TL50aJLWTextAQOUE%2BIROC&amp;TOPIC_ID=129934" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125433s032lbl.pdf#page=34</a></p></div>
<div class="block usep drugH1Div" id="F53570370"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of active polyarticular juvenile idiopathic arthritis (Simponi Aria: FDA approved in pediatric patients ages ≥2 years); treatment of acute psoriatic arthritis (Simponi Aria: FDA approved in ages ≥2 years and adults; Simponi: FDA approved in adults [alone or in combination with methotrexate]); treatment of moderately to severely active rheumatoid arthritis (in combination with methotrexate) (Simponi Aria, Simponi: FDA approved in adults); treatment of active ankylosing spondylitis (Simponi Aria: FDA approved in adults; Simponi: FDA approved in adults [alone or in combination with methotrexate]); treatment of moderately to severely active ulcerative colitis with corticosteroid dependence or who have had an inadequate response to conventional therapy (Simponi: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F50169189"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Golimumab may be confused with sarilumab.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299418"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F7734106"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Anti-Psoriasis Agents may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">InFLIXimab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53703305"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Treatment algorithms are available for use of biologics in female patients with Crohn disease who are planning a pregnancy (Weizman 2019). Serum levels should be optimized prior to conception (Mahadevan 2019).</p></div>
<div class="block pri drugH1Div" id="F7764743"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Golimumab crosses the placenta (Benoit 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Golimumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Following administration of golimumab 100 mg every 2 weeks throughout pregnancy to a patient with ulcerative colitis, cord blood concentrations of golimumab were 121% of the maternal serum concentration at delivery. Delivery occurred 3 days after the last maternal dose (Benoit 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to this class of medications is emerging, but based on available data, tumor necrosis factor alpha (TNFα) blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 776 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, &gt;27 weeks' gestation) (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low birth weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Use of immune modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 776 2019). When treatment for inflammatory bowel disease is needed in pregnant women, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For golimumab, the final injection can be given 4 to 6 weeks prior to the estimated date of delivery, then continued 48 hours' postpartum (Mahadevan 2019).</p></div>
<div class="block mopp drugH1Div" id="F53570371"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor improvement of symptoms and physical function assessments. Latent tuberculosis screening prior to initiating and during therapy; signs and symptoms of infection (prior to, during, and following therapy); CBC with differential; signs, symptoms, or worsening of heart failure; LFTs at baseline; hepatitis B virus (HBV) screening (all patients: prior to initiating; HBV carriers: during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs and symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), including periodic skin examination.</p></div>
<div class="block pha drugH1Div" id="F7764845"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Human monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), thereby interfering with endogenous TNFα activity. Biological activities of TNFα include the induction of proinflammatory cytokines (interleukin [IL]-6, IL-8, Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor), expression of adhesion molecules (E-selectin, vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule [ICAM]-1) necessary for leukocyte infiltration, activation of neutrophils and eosinophils.</p></div>
<div class="block phk drugH1Div" id="F7764847"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years (Xu 2019): SubQ:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;30 kg: Median: 6.05 L.</p>
<p style="text-indent:-2em;margin-left:6em;">30 to &lt;45 kg: Median: 7.52 L.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: Median: 12 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: 151 ± 61 mL/kg (distributed primarily to circulatory system with limited extravascular distribution).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: ~53%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Pathway unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years (Xu 2019):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;45 kg: Median: 7.53 days.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: Median: 11.9 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: SubQ: 2 to 6 days.</p></div>
<div class="block phksp drugH1Div" id="F51196150"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Following IV administration, patients with higher body weights tend to have higher serum golimumab concentrations (compared to lower body weights).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961950"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bio manguinhos golimumabe | Simponi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Simponi | Simponi aria</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Simponi aria</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Simponi | Simponi SmartJect</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Simponi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 776: immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol</i>. 2019;133(4):e287-e295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26311348">
<a name="26311348"></a>Bazzani C, Scrivo R, Andreoli L, et al. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. <i>Clin Exp Rheumatol</i>. 2015;33(5):688-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/26311348/pubmed" id="26311348" target="_blank">26311348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30445579">
<a name="30445579"></a>Benoit L, Mir O, Berveiller P. Treating ulcerative colitis during pregnancy: evidence of materno-fetal transfer of golimumab. <i>J Crohns Colitis</i>. 2019;13(5):669-670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/30445579/pubmed" id="30445579" target="_blank">30445579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22128083">
<a name="22128083"></a>Braun J, Baraliakos X, Hermann KG, et al. Golimumab Reduces Spinal Inflammation in Ankylosing Spondylitis: MRI Results of the Randomised, Placebo- Controlled GO-RAISE Study. <i>Ann Rheum Dis</i>. 2012;71(6):878-884.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/22128083/pubmed" id="22128083" target="_blank">22128083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30430682">
<a name="30430682"></a>Eworuke E, Panucci G, Goulding M, Neuner R, Toh S. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. <i>Pharmacoepidemiol Drug Saf</i>. 2019;28(3):296-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/30430682/pubmed" id="30430682" target="_blank">30430682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945371">
<a name="31945371"></a>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22505702">
<a name="22505702"></a>Genovese MC, Han C, Keystone EC, et al, “Effect of Golimumab on Patient-Reported Outcomes in Rheumatoid Arthritis: Results From the GO-FORWARD Study,” <i>J Rheumatol</i>, 2012, 39(6):1185-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/22505702/pubmed" id="22505702" target="_blank">22505702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29140944">
<a name="29140944"></a>Hyams JS, Chan D, Adedokun OJ, et al. Subcutaneous golimumab in pediatric ulcerative colitis: pharmacokinetics and clinical benefit. <i>Inflamm Bowel Dis</i>. 2017;23(12):2227-2237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/29140944/pubmed" id="29140944" target="_blank">29140944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18975305">
<a name="18975305"></a>Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis, Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. <i>Arthritis Rheum</i>. 2008;58(11):3402-3412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/18975305/pubmed" id="18975305" target="_blank">18975305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19333944">
<a name="19333944"></a>Kavanaugh A, Mcinnes I, Mease P, et al. Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis, Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study. <i>Arthritis Rheum</i>. 2009;60(4):976-986.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/19333944/pubmed" id="19333944" target="_blank">19333944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18383539">
<a name="18383539"></a>Kay J, Matteson EL, Dasgupta B, et al. Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate, A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. <i>Arthritis Rheum</i>. 2008;58(4):964-975.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/18383539/pubmed" id="18383539" target="_blank">18383539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19066176">
<a name="19066176"></a>Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a Human Antibody to TNF- α Given by Monthly Subcutaneous Injections, in Active Rheumatoid Arthritis Despite Methotrexate: The GO-FORWARD Study. <i>Ann Rheum Dis.</i> 2009;68(6):789-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/19066176/pubmed" id="19066176" target="_blank">19066176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22948700">
<a name="22948700"></a>Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis. <i>JAMA</i>. 2012;308(9): 898-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/22948700/pubmed" id="22948700" target="_blank">22948700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29961771">
<a name="29961771"></a>Luu M, Benzenine E, Doret M, et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). <i>Am J Gastroenterol</i>. 2018;113(11):1669-1677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/29961771/pubmed" id="29961771" target="_blank">29961771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29857090">
<a name="29857090"></a>Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. <i>Gastroenterology</i>. 2018;155(3):696-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/29857090/pubmed" id="29857090" target="_blank">29857090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26139307">
<a name="26139307"></a>Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. <i>Arthritis Rheumatol</i>. 2015;67(10):2702-2712. doi:10.1002/art.39257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/26139307/pubmed" id="26139307" target="_blank">26139307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simponi.1">
<a name="Simponi.1"></a>Simponi and Simponi IV (golimumab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simponi.2">
<a name="Simponi.2"></a>Simponi (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simponi.3">
<a name="Simponi.3"></a>Simponi (golimumab) [summary of product characteristics]. Leiden, Netherlands: Janssen Biologics B.V.; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simponi.4">
<a name="Simponi.4"></a>Simponi Aria (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simponi.5">
<a name="Simponi.5"></a>Simponi Aria (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25808588">
<a name="25808588"></a>Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. <i>Br J Clin Pharmacol</i>. 2015;80(4):727-739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/25808588/pubmed" id="25808588" target="_blank">25808588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22661646">
<a name="22661646"></a>Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous Golimumab is Effective in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy With Responses as Early as Week 2: Results of the Phase 3, Randomised, Multicentre, Double-Blind, Placebo-Controlled GO-FURTHER Trial. <i>Ann Rheum Dis</i>. 2013;72(3):381-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/22661646/pubmed" id="22661646" target="_blank">22661646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346529">
<a name="30346529"></a>Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of crohn's disease using RAND/UCLA appropriateness methodology. <i>Inflamm Bowel Dis.</i> 2019;25(2):328-335. doi:10.1093/ibd/izy333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/30346529/pubmed" id="30346529" target="_blank">30346529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30536638">
<a name="30536638"></a>Xu Y, Adedokun OJ, Chan D, et al. Population pharmacokinetics and exposure-response modeling analyses of golimumab in children with moderately to severely active ulcerative colitis. <i>J Clin Pharmacol</i>. 2019;59(4):590-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/golimumab-pediatric-drug-information/abstract-text/30536638/pubmed" id="30536638" target="_blank">30536638</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 129934 Version 69.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
